Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • March 17, 2017
  • Article
  • Science

How Economics Can Shape Precision Medicines

By: Ariel Dora Stern, Brian M. Alexander and Amitabh Chandra
  • Format:Print
ShareBar

Abstract

Many public and private efforts in coming years will focus on research in precision medicine, developing biomarkers to indicate which patients are likely to benefit from a certain treatment so that others can be spared the cost—financial and physical—of being treated with unproductive therapies while more easily uncovering therapeutic signals. However, such research initiatives alone will not deliver new medicines to patients in the absence of strong incentives to bring new products to market. We examine the unique economics of precision medicines and associated biomarkers, placing an emphasis on the factors affecting their development, pricing, and access.

Keywords

Health Care and Treatment; Research; Economics; Motivation and Incentives

Citation

Stern, Ariel Dora, Brian M. Alexander, and Amitabh Chandra. "How Economics Can Shape Precision Medicines." Science 355, no. 6330 (March 17, 2017): 1131–1133.
  • Find it at Harvard
  • Register to Read

About The Authors

Ariel D. Stern

Technology and Operations Management
→More Publications

Amitabh Chandra

Technology and Operations Management
→More Publications

More from the Authors

    • Harvard Business Manager

    Ein Booster für die Pharmabranche: Gerade erst hat die mRNATechnologie geholfen, Impfstoffe gegen Covid-19 zu entwickeln. Nun könnte sie wie Apples iOS die Grundlage für neue Innovationsplattformen bieten.

    By: Ariel Dora Stern, Timo Minssen, W. Nicholson Price, II and Christoph Grimpe
    • April 18, 2022
    • Harvard Business Review (website)

    Will mRNA Technology Companies Spawn Innovation Ecosystems?

    By: Christoph Grimpe, Timo Minssen, W. Nicholson Price, II and Ariel Dora Stern
    • April 2022
    • NEJM Catalyst Innovations in Care Delivery

    AI Insurance: How Liability Insurance Can Drive the Responsible Adoption of Artificial Intelligence in Health Care

    By: Ariel Dora Stern, Avi Goldfarb and Timo Minssen
More from the Authors
  • Ein Booster für die Pharmabranche: Gerade erst hat die mRNATechnologie geholfen, Impfstoffe gegen Covid-19 zu entwickeln. Nun könnte sie wie Apples iOS die Grundlage für neue Innovationsplattformen bieten. By: Ariel Dora Stern, Timo Minssen, W. Nicholson Price, II and Christoph Grimpe
  • Will mRNA Technology Companies Spawn Innovation Ecosystems? By: Christoph Grimpe, Timo Minssen, W. Nicholson Price, II and Ariel Dora Stern
  • AI Insurance: How Liability Insurance Can Drive the Responsible Adoption of Artificial Intelligence in Health Care By: Ariel Dora Stern, Avi Goldfarb and Timo Minssen
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College